Prelude Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $5,704 | $4,580 | $5,640 | $6,500 |
Gross Profit | 5,704 | 4,189 | 5,640 | 6,500 |
EBITDA | -13,568 | -9,994 | -16,039 | -19,300 |
EBIT | -13,921 | -10,385 | -16,457 | -19,725 |
Net Income | -13,921 | -10,385 | -16,457 | -19,725 |
Net Change In Cash | 5,704 | 4,580 | 5,640 | 6,500 |
Free Cash Flow | -15,574 | -21,685 | 23,119 | -19,115 |
Cash | 26,329 | 21,756 | 35,256 | 47,532 |
Basic Shares | 98,388 | 82,519 | 62,953 | 76,132 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $12,140 | $7,000 | $0 | $0 |
Gross Profit | 10,429 | 7,000 | -1,169 | -3,042 |
EBITDA | -97,787 | -125,401 | -120,663 | -122,216 |
EBIT | -99,498 | -127,173 | -121,832 | -123,540 |
Net Income | -99,498 | -127,173 | -121,832 | -107,336 |
Net Change In Cash | 12,140 | 7,000 | 0 | 0 |
Free Cash Flow | -56,369 | -103,652 | -110,576 | -86,748 |
Cash | 35,256 | 12,474 | 25,291 | 30,605 |
Basic Shares | 76,956 | 75,805 | 60,357 | 47,371 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.14 |
2026-03-31 | -$0.13 |
2025-12-31 | -$0.20 |
2025-09-30 | -$0.26 |